Buchang Pharma released its 2026 interim report. Total operating revenue was 5.003 billion yuan, down 11.67% from the same period last year. Net profit attributable to the parent company was 503 million yuan, down 19.93% year-on-year. Net cash inflow from operating activities was 298 million yuan, a sharp year-on-year decline of 68.96%. The company's latest asset-liability ratio was 50.88%, gross margin was 61.19%, and diluted earnings per share was 0.48 yuan, down 19.33% year-on-year. The number of shareholders was 49,400, and the top ten shareholders held 65.20% of total share capital.
Shandong Buchang Pharmaceuticals Co LtdNet profit down 19.93% and operating cash flow down 68.96% in interim report.
